Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Edwards Lifesciences, LLC

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Edwards Lifesciences, LLC

Regulatory records
104
Linked recall entries
8
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 104 FDA records to the applicant name Edwards Lifesciences, LLC. The collection includes 2 510(k) clearances. It includes 9 original PMA approvals. 26 entries are PMA supplements. 67 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Sep 26, 1991 to Oct 28, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code NPT appears in 21 of the 104 linked filings. The collection spans 11 FDA product codes and 9 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P140031, with 21 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 22 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: One Edwards Way, Irvine, CA, 92614. Recorded on P150048/S104, decision dated Oct 28, 2026.

Changes described in PMA records

P150048/S104: INSPIRIS RESILIA Aortic Valve (11500A), KONECT RESILIA Aortic Valve Conduit (AVC) (11060A), MITRIS RESILIA Mitral Valv

The FDA record for P150048/S104 is a 30-day notice supplement, reason listed as process change affecting manufacturer, sterilizer, packager or supplier. The reported purpose is implementing an alternative supplier of a chemical manufacturing aid, linked to the INSPIRIS RESILIA aortic valve (11500A), KONECT RESILIA aortic valve conduit (AVC) (11060A) and MITRIS RESILIA mitral valve under product code LWR.

The identifier P150048 places this change within the existing PMA for the Edwards Lifesciences devices named, but the decision is a supplement, not a new approval of the whole system. The record does not identify the chemical aid, name either supplier, describe the manufacturing step, or give data on device safety or clinical performance. The purpose is reported by the applicant in the source statement and is not independent proof of safety or effectiveness.

The record carries decision code OK30 dated 2026-10-28, giving no further grounds for the decision.

FDA approval-order wording

implementing an alternative supplier of a chemical manufacturing aid

Oct 28, 2026 · 30-Day Notice

P200015/S084: Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX)

Edwards Lifesciences, LLC filed PMA supplement P200015/S084 for the SAPIEN 3 Transcatheter Heart Valve (9600TFX), a percutaneously delivered pulmonary valve prosthesis under product code NPV. The FDA record lists it as a 30-Day Notice with decision OK30, dated 2026-10-28. The supplement reason field cites a process change involving manufacturer, sterilizer, packager, or supplier, and the statement describes implementing an alternative supplier of a chemical manufacturing aid.

The supplement number ties this action to PMA P200015, but it is a notice about a supplier change, not an original approval of the valve system. The fields do not name the chemical manufacturing aid, the prior or replacement supplier, the affected manufacturing step, or any supporting data. The reported purpose does not by itself establish safety or clinical effectiveness, and no clinical or regulatory conclusion beyond this descriptive record is supported.

The available source does not specify which category—manufacturer, sterilizer, packager, or supplier—applies, nor identify the device component affected. Researchers should treat the stated purpose as the applicant's notice content rather than corroborated evidence of device performance.

FDA approval-order wording

implementing an alternative supplier of a chemical manufacturing aid

Oct 28, 2026 · 30-Day Notice

P140031/S210: Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX), Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (9750TFX)

This 30-Day Notice for supplement S210 to PMA P140031 records a process change: implementing an alternative supplier of a chemical manufacturing aid. The affected devices are the Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX) and the Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (9750TFX), both percutaneously delivered aortic valve prostheses under product code NPT.

The notice does not state which chemical manufacturing aid, which manufacturing step, or which supplier is involved. The FDA decision field reads "OK30," but the source does not define that code. This supplement is not a new approval of the valve systems and does not establish safety or effectiveness; it only reports the supplier change.

FDA approval-order wording

implementing an alternative supplier of a chemical manufacturing aid

Oct 28, 2026 · 30-Day Notice

P230013/S034: Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)

The FDA record for P230013/S034 describes a 30-day notice, dated 2026-10-28, with a reported purpose of implementing an alternative supplier of a chemical manufacturing aid. The listed supplement reason is a process change covering manufacturer, sterilizer, packager or supplier. The applicant is Edwards Lifesciences, LLC, and the product code is NPW, in the cardiovascular specialty.

The identifier ties the notice to the original PMA P230013, and the title names the Edwards EVOQUE tricuspid valve replacement system (9850EV). That relationship identifies the affected filing but does not make this supplement a new approval of the whole system, and a manufacturing notice is not an original PMA. The record does not name the chemical manufacturing aid, the prior or replacement supplier, affected lots or models, or any supporting data. The stated purpose is not independent proof of safety or clinical effectiveness, and the record supports no clinical or regulatory conclusion beyond this description.

FDA approval-order wording

implementing an alternative supplier of a chemical manufacturing aid

Oct 28, 2026 · 30-Day Notice

P860057/S228: Carpentier-Edwards PERIMOUNT Theon RSR Pericardial Aortic Bioprosthesis with ThermaFix tissue process (2800TFX), Carpen

This 30-day notice for supplement S228 to PMA P860057 states that the change is implementing an alternative supplier of a chemical manufacturing aid. The affected device is the Carpentier-Edwards PERIMOUNT Theon RSR Pericardial Aortic Bioprosthesis with ThermaFix tissue process (2800TFX), a replacement heart valve under product code DYE.

The notice does not describe the chemical manufacturing aid, the previous or alternative supplier, or any resulting process validation. It also does not state that safety or clinical effectiveness was independently demonstrated. The supplement type is a process change involving manufacturer, sterilizer, packager, or supplier, and it does not constitute a new approval of the valve system.

FDA approval-order wording

implementing an alternative supplier of a chemical manufacturing aid

Oct 28, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 8 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 7 Class I, 1 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Recall / productCompanyClassificationReport dateSource
Edwards Lifesciences, LLCClass INov 11, 2026FDA
Edwards Lifesciences, LLCClass IIMay 20, 2026FDA
Edwards Lifesciences, LLCClass IJul 16, 2025FDA
Edwards Lifesciences, LLCClass IJul 16, 2025FDA
Edwards Lifesciences, LLCClass IJul 16, 2025FDA
Edwards Lifesciences, LLCClass IJul 16, 2025FDA

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Search the firm’s recall records
Source information

Source updated Nov 11, 2026. Retrieved Nov 21, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 27, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 22, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 22, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 22, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 21, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 20, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 19, 2026FDA
Edwards Lifesciences, LLCPMA approvalOct 1, 2026FDA
Edwards Lifesciences, LLCPMA supplementSep 23, 2026FDA
Edwards Lifesciences, LLCPMA supplementSep 23, 2026FDA
Edwards Lifesciences, LLCPMA supplementSep 23, 2026FDA
Edwards Lifesciences, LLCPMA supplementSep 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementSep 9, 2026FDA
Edwards Lifesciences, LLCPMA supplementAug 5, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 28, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 28, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 28, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 17, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 17, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 2, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 2, 2026FDA
Edwards Lifesciences, LLCPMA supplementJun 30, 2026FDA
Edwards Lifesciences, LLCPMA supplementJun 30, 2026FDA
Edwards Lifesciences, LLCPMA supplementJun 18, 2026FDA
Edwards Lifesciences, LLC510(k) clearanceJun 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementJun 4, 2026FDA
Edwards Lifesciences, LLCPMA supplementJun 3, 2026FDA
Edwards Lifesciences, LLCPMA supplementJun 3, 2026FDA
Edwards Lifesciences, LLCPMA supplementJun 3, 2026FDA
Edwards Lifesciences, LLCPMA supplementMay 26, 2026FDA
Edwards Lifesciences, LLCPMA supplementMay 26, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 30, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 21, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 10, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 9, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 9, 2026FDA
Edwards Lifesciences, LLCPMA supplementMar 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementMar 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementMar 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementMar 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementMar 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementMar 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementMar 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 27, 2026FDA
Edwards Lifesciences, LLC510(k) clearanceFeb 24, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 19, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 12, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 12, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 12, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 6, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 6, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 3, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 2, 2026FDA
Edwards Lifesciences, LLCPMA supplementJan 28, 2026FDA
Edwards Lifesciences, LLCPMA approvalDec 22, 2025FDA
Edwards Lifesciences, LLCPMA supplementDec 17, 2025FDA
Edwards Lifesciences, LLCPMA supplementDec 17, 2025FDA
Edwards Lifesciences, LLCPMA supplementDec 17, 2025FDA
Edwards Lifesciences, LLCPMA supplementNov 19, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 31, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 27, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 16, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 16, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 16, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 16, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 16, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 10, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 2, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 2, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 2, 2025FDA
Edwards Lifesciences, LLCPMA supplementSep 25, 2025FDA
Edwards Lifesciences, LLCPMA supplementSep 12, 2025FDA
Edwards Lifesciences, LLCPMA supplementSep 9, 2025FDA
Edwards Lifesciences, LLCPMA supplementAug 13, 2025FDA
Edwards Lifesciences, LLCPMA supplementJul 25, 2025FDA
Edwards Lifesciences, LLCPMA supplementJul 23, 2025FDA
Edwards Lifesciences, LLCPMA approvalFeb 1, 2024FDA
Edwards Lifesciences, LLCPMA approvalSep 14, 2022FDA
Edwards Lifesciences, LLCPMA approvalAug 31, 2020FDA
Edwards Lifesciences, LLCPMA approvalJun 29, 2017FDA
Edwards Lifesciences, LLCPMA approvalAug 12, 2016FDA
Edwards Lifesciences, LLCPMA approvalJun 17, 2015FDA
Edwards Lifesciences, LLCPMA approvalSep 26, 1991FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.